In a laboratory study, the Pfizer vaccine in BioNTech demonstrated efficacy against the Brazilian coronavirus variant

The vaccine against Pfizer’s and BioNTech’s covid-19 has shown a high capacity to neutralize the coronavirus virus that is spreading rapidly in Brazil, following a new study.

In laboratory experiments, the vaccine demonstration levels “approximately equivalent” of neutralizing activity against the Brazilian and British caps and comparison with a version of the principles of the past. Also most active activity “robust pero menor” in front of the South African variant, follow a map to New England Journal of Medicine.

If the investigation should be validated with real world data, offers another reason for the optimism that vacancies will generally work well against virus variants.

The research carried out by Pfizer in BioNTech and carried out by scientists of the medical framework of the University of Texas of Galveston, Texas.

The most trusted studio the extraction of persona to which the vaccine is administered The vaccine neutralizes a designed version of the virus that contains the various mutations that are found in the portion of the specific variant P.1, first identified in Brazil.

The scientists say that the neutralizing capacity was approximately equivalent to the effect of the vaccine in an anterior version less contagious of the virus passed.

The species used by the virus to enter human cells is the main objective of many covid-19 vacancies.

In previously published studies, Pfizer has discovered that its vaccine neutralizes other highly contagious variants first identified in the United Kingdom and South Africa, although the South African variant can reduce the anti-body protectors provoked by the vaccine.

If there are developers, including BioNTech, they are working on new versions of its vehicles to combat the mutated animals, the actual generation of vehicles against the covid ya is showing some results results alentadores contrast welding variant.

Pfizer has said that it is very likely that its current vaccine will be sold against the South African variant. Without embarrassment, the drug manufacturer plans to try a third dose of refueling of its vaccine, as well as a version redesigned specifically to combat the variant with the end to better understand the immune response.

La vacuna de AstraZeneca Plc also offers proportional protection against the Brazilian variant, information Reuters, citing the biomedical institute Fiocruz del país.

Prohibition of probes, the one that was encountered for the first time in South Africa has always been more difficult to attack. The Paisens commenced to use the Johnson & Johnson vacancies my past to its initial inoculations when a small study showed that the AstraZeneca vaccine has had a small impact on the infections caused by the variant.

(With Reuters information y Bloomberg)

SEGUIR LEYENDO: